Wall Street liked the news. When Acadia Healthcare named Debbie Osteen as chief executive in January 2026, global investment bank Jefferies said it “view[ed] the announcement this morning that Debbie Osteen is returning to Acadia as its CEO positively”. Reeve Waud, the company’s board chairman, had already framed the appointment as a move toward experienced leadership.

That favorable read rested on Osteen’s record. Few candidates could match the behavioral health experience she brought back to Acadia Healthcare.

Decades in Behavioral Health

Jefferies pointed straight to her tenure across two major operators. She “brings decades of experience in the behavioral health industry, having run both Acadia and Universal Health’s behavioral business, prior to her departure from ACHC in 2022,” the bank said.

That dual experience is uncommon. Leading the behavioral divisions at two of the largest operators in the United States gave Osteen a wide view of the field, from facility operations up to industry strategy.

Why the Endorsement Carries Weight

Reeve Waud’s own read matched the analyst view. He called Osteen “a mission-driven executive with a commitment to patients who helped transform Acadia into the leading provider of behavioral healthcare in the U.S.”.

When the board chairman and an outside bank land in the same place, it says something. Both saw a leader stepping into Acadia Healthcare with credentials already proven. That’s exactly what a company wants when it names a chief executive to lead during a succession search.